Enrolling Studies


Prostate Cancer:

  1. Myriad Genetic Laboratories, Inc.     Protocol: URO-008

     - a long-term data collection registry study to evaluate treatment decisions and clinical outcomes in  

       men age 65 and older with favorable intermediate-risk prostate cancer 

  1. Bayer HealthCare Pharmaceuticals, Inc.      Protocol: 20609

      - a study to compare the effects of treatment between two medications on physical function and daily   

        activity in men with castration-resistant prostate cancer


Enteric Hyperoxaluria:

  1. Allena Pharmaceuticals    Protocol: ALLN-177-302

      - kidney stone study to evaluate a medication to reduce oxalate excretion in patients with a history of  

         bariatric surgery, Crohn’s disease, short bowel or other malabsorption syndromes


Muscle Invasive Bladder Cancer:

  1. Animated Dynamics, Inc.    Protocol: Onco4D (™) Biodynamic Chemotherapy Selection Assay

    - a feasibility study of Motility Contrast Tomography for suspected muscle-invasive bladder cancer


Bladder Cancer:

  1. Altor Bioscience (Immunity Bio)   Protocol: QUILT-3.032

    - a study for patients with BCG unresponsive high-grade non-muscle invasive bladder cancer

  1. Altor Bioscience (Immunity Bio)   Protocol QUILT-2.005

    - a study for patients with high-grade non-muscle invasive bladder cancer who have never received 

     BCG treatment


Overactive Bladder in Men:

  1. Urovant Sciences   Protocol URO-901-3005

      -  a study for males age 45 and older with overactive bladder symptoms currently on medication 

          therapy for enlarged prostate